Patient non-adherence to prescribed medication regimens is a significant problem and affects clinical treatment outcomes. The MemoPatch™ medical device, currently in development, is an electronic skin patch intended to deliver tactile medication reminder signals. Fifty volunteers completed a laboratory experiment that evaluated the detectability and appraisal thresholds of five split signals; specifically, the current thresholds (in mA) at which a signal was detected (threshold T1), was considered sufficiently detectable to serve as a reminder signal (threshold T2), and became too strong as a reminder signal (threshold T3). Signals were selected under consideration of three data points: T1Max and T2Max (defined as, resp., the maximum current observed at T1 and T2) and T3Pct90 (the T3 current at the 90(th) percentile). A signal was considered to be useable in future versions of the MemoPatch™ device if it met the constraint that (T3Pct90-T2Max) should not be negative. One signal met the constraint requirement as its T3Pct90-T2Max=0.96mA.

Download full-text PDF

Source
http://dx.doi.org/10.1109/EMBC.2013.6609650DOI Listing

Publication Analysis

Top Keywords

detectability appraisal
8
appraisal thresholds
8
thresholds split
8
memopatch™ device
8
electronic skin
8
skin patch
8
patch intended
8
intended deliver
8
deliver tactile
8
tactile medication
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!